For decades, and in the exceptional instance of the Institut Pasteur for over a century, non-profit organizations have augmented R&D to advance scientific understanding and develop affordable and accessible pipelines of vaccines, medicines and diagnostics. Small and medium enterprises and former biopharmaceutical industry executives make a sizeable contribution to global health goals by pursuing opportunities in this corner of the global biopharmaceutical ecosystem.
This is a preview of subscription content, access via your institution
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$32.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to the full article PDF.
USD 39.95
Prices may be subject to local taxes which are calculated during checkout
References
Willis, J. R. et al. Science https://doi.org/10.1126/science.adr8382 (2025).
Impact Global Health. The 2025 neglected disease R&D pipeline review: time to close the gaps. https://www.impactglobalhealth.org/insights/report-library/the-2025-neglected-disease-rd-pipeline-review (2025).
Impact Global Health. 100 Days Mission: 4th implementation report and scorecard. https://www.impactglobalhealth.org/insights/report-library/ipps-report-2025 (2025).
Levinson, K. J. et al. Vaccines https://doi.org/10.1016/j.vaccine.2016.10.023 (2016).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Nasto, B. Non-profits wade in where for-profit life science investment fears to tread. Nat Biotechnol 43, 1221–1226 (2025). https://doi.org/10.1038/s41587-025-02752-3
Published:
Version of record:
Issue date:
DOI: https://doi.org/10.1038/s41587-025-02752-3
This article is cited by
-
Response to ‘Non-profits wade in where for-profit life science investment fears to tread’
Nature Biotechnology (2026)
